JOSE ANTONIO
GIRON GONZALEZ
Catedrático de Universidad
Hospital Universitario Virgen Macarena
Sevilla, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Virgen Macarena (18)
2023
-
Direct-acting oral anticoagulants in antiphospholipid syndrome: A systematic review
Medicina Clinica, Vol. 161, Núm. 2, pp. 65-77
2021
-
Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials
BMC Infectious Diseases, Vol. 21, Núm. 1
-
Modifications of CD4 T cells, CD4/CD8 ratio and serum levels of soluble CD14 in HIV-HCV-coinfected patients after sustained HCV response induced by direct-acting antiviral agents: influence of liver cirrhosis
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 40, Núm. 9, pp. 1863-1871
2019
-
Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects
Journal of Neuroimmune Pharmacology, Vol. 14, Núm. 3, pp. 413-422
2018
-
Diagnosis and empirical treatment for community-acquired pneumonia in special situations: immunocompromised HIV negative and elderly patients
Medicine (Spain), Vol. 12, Núm. 53, pp. 3168-3173
-
Diagnostic and therapeutic protocol for community-acquired pneumonia
Medicine (Spain), Vol. 12, Núm. 53, pp. 3162-3167
-
Diagnostic and therapeutic protocol for pleural infections
Medicine (Spain), Vol. 12, Núm. 54, pp. 3231-3234
-
Unsolicited consultation by infectious diseases specialist improves outcomes in patients with bloodstream infection: A prospective cohort study
Journal of Infection, Vol. 77, Núm. 6, pp. 503-508
2017
-
Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 3, pp. 487-494
2015
-
Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 9, pp. 1879-1884
2013
-
Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis
Clinical Infectious Diseases, Vol. 56, Núm. 11, pp. 1646-1653
2012
-
Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients
AIDS, Vol. 26, Núm. 13, pp. 1721-1724
-
Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis
Clinical Infectious Diseases, Vol. 55, Núm. 12, pp. 1719-1726
2008
-
Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients
AIDS, Vol. 22, Núm. 8, pp. 923-930
-
Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen
Journal of Antimicrobial Chemotherapy, Vol. 62, Núm. 4, pp. 793-796
-
Liver toxicity of antiretroviral combinations including atazanavir/ ritonavir in patients co-infected with HIV and hepatitis viruses: Impact of pre-existing liver fibrosis
Journal of Antimicrobial Chemotherapy, Vol. 61, Núm. 4, pp. 925-932
2007
-
Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients
Journal of Antimicrobial Chemotherapy, Vol. 60, Núm. 6, pp. 1347-1354
-
Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients
Antiviral Therapy, Vol. 12, Núm. 8, pp. 1225-1235